|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | 0.00% |
|
0.00% | 0.00% |
| Mar. 22 | Disclosure Statement and Plan Approved on Interim Basis for Pear Therapeutics, Inc. | CI |
| Mar. 04 | Combined Liquidation Plan and Disclosure Statement Filed by Pear Therapeutics, Inc. | CI |
Pear Therapeutics, Inc. reaffirmed revenue guidance for the full year 2022. For the year, reaffirmed its $22 million revenue guidance.
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 142 | |
| +33.79% | 50.85B | |
| +0.70% | 42.82B | |
| +49.62% | 42.03B | |
| -4.96% | 29.55B | |
| +10.88% | 26.11B | |
| -21.63% | 19.13B | |
| +9.28% | 13.05B | |
| +27.29% | 12.16B | |
| +23.96% | 12.08B |
PEAR THERAPEUTICS, INC. 